Abstract
This study sought to determine outcomes for patients with metastatic breast cancer (MBC) with no evidence of disease (NED) after treatment and to identify factors predictive of outcomes once the status of NED was attained. This study reviewed 570 patients with MBC who were consecutively treated between January 2003 and December 2005. Ninety patients (16%) attained NED, which was defined as a complete metabolic response on positron emission tomography or sclerotic healing of bone metastases on computed tomography or magnetic resonance imaging. The median follow-up for patients attaining NED was 100 months (range, 14-134 months). The 3- and 5-year overall survival (OS) rates were 44% and 24%, respectively, for the entire group and 96% and 78%, respectively, for those attaining NED. According to a landmark analysis, NED status was significantly associated with survival at 2 (P < .001; hazard ratio [HR], 0.23; 95% confidence interval [CI], 0.16-0.34) and 3 years (P < .001; HR, 0.20; 95% CI, 0.14-0.30). From the time of NED, the median survival was 102 months (range, 14-134 months) with 5-year OS and progression-free survival (PFS) rates of 77% and 40%, respectively. According to a multivariate analysis, human epidermal growth facto...Continue Reading
References
Jan 1, 1979·Journal of Surgical Oncology·A U BuzdarE A Gehan
Oct 1, 1990·Cancer·G FalksonC I Falkson
Aug 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P A GreenbergA U Buzdar
Jan 28, 1999·Cancer·Z U RahmanG N Hortobagyi
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Gabriel N Hortobagyi
Dec 24, 2003·Cancer·Sharon H GiordanoGabriel N Hortobagyi
Feb 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Rebecca G HagertyMartin H N Tattersall
Aug 30, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shaheenah DawoodSharon H Giordano
Oct 28, 2008·Palliative Medicine·S Innes, S Payne
Mar 25, 2009·Nature Reviews. Cancer·Don X NguyenJoan Massagué
Mar 12, 2010·Journal of the National Cancer Institute·Olivia PaganiUNKNOWN ESO-MBC Task Force
Apr 30, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DawoodS H Giordano
Jul 31, 2010·The Oncologist·Jean-Marc ExtraMoïse Namer
Dec 30, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Belinda E KielyMartin R Stockler
Apr 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alessandra GennariPaolo Bruzzi
May 14, 2011·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Yee Chung Cheng, Naoto T Ueno
May 10, 2013·Internal Medicine Journal·E S ThientosapolB E Kiely
Nov 2, 2013·Therapeutic Advances in Medical Oncology·Raffaella PalumboAntonio Bernardo
Oct 4, 2014·SpringerPlus·Rudolf WeideHubert Köppler
Citations
Sep 28, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S T ButterbaughA Mathew
Oct 26, 2018·Annals of Surgical Oncology·Atilla Soran
Sep 8, 2019·Breast Cancer Research and Treatment·T G SteenbruggenG S Sonke
Aug 25, 2018·The Oncologist·Yao WongRashmi K Murthy
Nov 5, 2017·Oncotarget·Floriana MorgilloMichele Orditura
Oct 13, 2018·Journal of the National Cancer Institute·Elisabeth TrappUNKNOWN SUCCESS Study Group
Dec 20, 2018·Advances in Therapy·Marina E CazzanigaValter Torri
Oct 12, 2019·Scientific Reports·Munmi MajumderRupak Mukhopadhyay
May 9, 2019·Breast Cancer Research and Treatment·B M AartsG Maleux
Jan 7, 2017·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Giulia GalliSerena Di Cosimo
Jan 8, 2020·Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznań and Polish Society of Radiation Oncology·Marta BonetUNKNOWN Grup Oncològic Català Occità (GOCO Group)
Nov 17, 2021·Bioengineered·Yanlong ShiHongzhu Yu